简体中文
Innovation
NASH
Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), accompanied by inflammation and liver fibrosis, which can directly lead to liver cirrhosis, liver cancer and promote chronic liver diseases.
More
T2DM
Diabetes mellitus type 2 (T2DM), formerly known as noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes, is a chronic metabolic disease which occurs more frequently after 35~40 years of age, accounting for over 90% of patients with diabetes.
More
Renal Anemia
Renal anemia refers to anemia caused by absolute or relative insufficient production of erythropoietin (EPO) caused by various renal diseases and uremic toxin. Anemia is a common clinical manifestation in patients with renal disease. It is an important complication of renal disease.
More
About Beryl
Company Introduction > >
Xiamen Beryl Therapeutics, Ltd. is an innovative drug R & D company located in Xiamen Biopharmaceutical Park. It aims at developing organ-targeted small-molecule drugs for unmet medical needs including organ fibrosis and metabolic diseases.
More
Pipeline
Our pipelines include discovery and development of small-molecule drugs against fibrotic diseases, diabetes and renal anemia with the focus on early stages (from discovery to phase II).
More
Team
The technical team is composed of Ph.D. and master-leveled scientists with a majority overseas-trained. They are well experienced in pharmaceutical R&D, management and commercialization. Their training and specialties cover all the key technical fields related to drug R&D, such as drug design and synthesis, screening, drug action mechanism research, quality control and new drug registration. They have the technical strength, experience and foundation to build a world-class innovative drug R&D enterprise.
More
Baidu
sogou